Estadístiques de Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Visites totals

views
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma 269

Visites totals per mes

views
October 2024 0
November 2024 4
December 2024 0
January 2025 0
February 2025 0
March 2025 0
April 2025 0

Visites al fitxer

views
bellmunt-njm-pemb.pdf(legacy) 279
bellmunt-njm-pemb.pdf 25

Vistes principals per país

views
United States 187
Germany 11
South Korea 10
Spain 9
Japan 6
Australia 4
Canada 4
United Kingdom 4
Belgium 3
China 3
Denmark 2
France 2
Iran 2
Italy 2
Taiwan 2
Bahrain 1
Brazil 1
Cameroon 1
European Union 1
Israel 1
India 1
Mexico 1
Malaysia 1
Netherlands 1
New Zealand 1
Russia 1
Sweden 1
Turkey 1
South Africa 1

Visites principals per ciutat

views
Ashburn 38
Fairfield 28
San Ramon 14
Redwood City 13
Cambridge 10
Barcelona 7
Boardman 6
Ann Arbor 5
Busan 4
Menlo Park 4
Mountain View 4
Philadelphia 4
Falls Church 3
Los Angeles 3
Melbourne 3
San Diego 3
Seoul 3
Shenzhen 3
Beaumont 2
Farum 2
Phoenix 2
Rochester 2
Rockville 2
Seattle 2
Stevenage 2
Tokyo 2
Azusa 1
Brussels 1
Cardiff 1
Delhi 1
Durban 1
Englewood Cliffs 1
Freiburg 1
Fremont 1
Gent 1
Houston 1
Istanbul 1
Jerusalem 1
La Laguna 1
Laguna Niguel 1
Leeds 1
Magdeburg 1
Manama 1
Mexico 1
Milan 1
Mississauga 1
Monticello 1
Montréal 1
Moscow 1
Narberth 1
New York 1
Newark 1
Ottawa 1
Piemonte 1
Piscataway 1
Portland 1
Premiá De Mar 1
Rio De Janeiro 1
Salem 1
Shah Alam 1
Taipei 1
Tsukuba 1
Wellington 1